November 14, 2016: Antimicrobials: Reducing Need for Antibiotics
What will kill more people than cancer? What will cost us over $100 trillion dollars unless we develop antimicrobial resistance alternatives soon? Preventing infections from spreading is one alternative. Developing new ways to kill bacteria and fungi is another. Experts taking each path will explain.
Getting an infection is bad enough, but getting one while in a hospital’s clean environment should be unheard of. Healthcare-associated infections (HAIs) – infections patients can get while receiving medical treatment in a healthcare facility–are a major, yet often preventable, threat to patient safety. In 2011, there were an estimated 722,000 HAIs in U.S. acute care hospitals. Additionally, about 75,000 patients with HAIs died during their hospitalizations. When healthcare facilities, care teams, and individual doctors and nurses are aware of infection problems and take specific steps to prevent them, rates of some targeted HAIs (e.g., Central Line Associated Blood Stream Infections, CLABSI) can decrease by more than 70 percent. But despite better efforts, between 2009 and 2014 there was no change in overall catheter-associated urinary tract infections (CAUTI).
Lisa Maloney of Sciessent LLC will teach us how applying an antimicrobial coating to surfaces that patients and hospital people touch can reduce the transmission of infections within a healthcare facility. These antimicrob-ials can also be mixed into the materials of medical devices to prevent bacteria from colonizing the devices.
Todd Alexander of AMProtection will explain why chemically binding a bacteria-killing molecule to the surfaces of urinary catheters can prevent catheter-associated urinary tract infections. These bound antimicrobial peptides are not consumed while killing bacteria, so last a long time and could not only prevent CAUTI but reduce the frequency of uncomfortable urinary catheter changes.
Our panel shares their company’s advances and where the state-of-the-art is taking us.
- Lise Moloney, Director, Business Development – Healthcare, Sciessent LLC
- Todd Alexander, CEO and Co-Founder, AMProtection
- Lindsay Lozeau, AMProtection
- Brad Prosek is President of All Terrain bioPartners
Todd Alexander is CEO and Co-Founder of AMProtection, and is a Fellow at The University Innovation Fellows program is managed by the National Center for Engineering Pathways to Innovation (Epicenter). Todd holds a BS and MS in Chemical Engineering from WPI.
Lindsay Lozeau, a PhD candidate in chemical engineering at WPI, is co-founder and Chief Technology Officer of AMProtection. She has been awarded two fellowships (NSF IGERT and Hitchcock) and has made two first place elevator pitches at WPI and one at The Venture Forum in Worcester. She also has industry experience working at Kimball Physics, Inc. and TEI Biosciences. Currently her PhD work, aimed toward the use and delivery of antimicrobial peptides in collagen-based wound dressings, is funded under an NSF STTR grant and is nearing license.She holds a BS in Chemical Engineering from URI and is in the PhD program at WPI.
Lise Moloney has over 15 years of experience in the antimicrobial additive and medical device fields in both R&D and business development. Her experience includes market development, product development, technology assessment and regulatory strategy. At Sciessent, Lise plays a key role in strategic planning and execution of marketing the company’s Agion antimicrobial technology to the healthcare industry. Prior to joining Sciessent Lise was with Covidien, where she held several R&D positions, including Group Leader in Advanced Research, vetting new technologies and establishing Clinical Advisory Boards to guide and support advanced research programs.
Brad Prosek is President of All Terrain bioPartners LLC, a life sciences advisory group, and was previously Head, Infection Prevention Technology & Services, for Cubist Pharmaceuticals, broadening the solutions Cubist could deliver to hospital systems fighting the rising tide of antibiotic-resistant bacteria. Before that he served as Senior Director, Corporate Development for Cubist Pharmaceuticals, Inc. In this role, Brad focused on transactions supporting Cubist’s drug pipeline build-out. Previously at Cubist, Brad started and led the Market Access group, which focused on developing non-hospital markets for the company’s flagship product CUBICIN (daptomycin for injection). He joined Cubist in 2005 from Biogen Idec, Inc., bringing ten years of global healthcare strategy, operating, and consulting experience. Brad holds an M.B.A. from Columbia Business School and a B.S.F.S from Georgetown University’s Walsh School of Foreign Service.
Committee: Jerry Shapiro, Mark Hediger, Carmel Denis, Howard Lin
Co-Chairs, Jerry Shapiro and Barbara Finer
Contact our Chair with questions or if you want to volunteer in some capacity (Jerrold)